Brad Plummer PhDinBiotech ValuationThe Future of Cardiac Gene TherapyThe demise of Celladon and the evaporation of $360,000,000Apr 28, 2015Apr 28, 2015
Brad Plummer PhDinBiotech ValuationAtrial Fibrillation in 2015: Burn it AllAtrial fibrillation (AF) is the most common irregular heart rhythm (e.g. arrhythmia) and will affect 1 in 4 people.Feb 4, 2015Feb 4, 2015
Brad Plummer PhDinBiotech ValuationCellular Dynamics International at #JPM15: Time for iPSC therapies?Robert Palay, CEO and Emile Newaysir, COO for Cellular Dynamics Technology (CDI, $ICEL) took the stage Wednesday, January 14th at the J.P…Jan 16, 20151Jan 16, 20151
